Abstract The approval of the first kinase inhibitor, Gleevec, ushered in a paradigm shift for oncological treatment-the use of genomic data for targeted, efficacious therapies. Since then, over 48 additional small-molecule kinase inhibitors have been approved, solidifying the case for kinases as a highly druggable and attractive target class. Read more “The Clinical Kinase Index: Prioritizing Understudied Kinases at Targets for the Treatment of Cancer”
It’s part genomics*, part big data, and all about driving discoveries that could someday translate to new treatments for cancer, neurological diseases, addiction, and many other conditions, said Stephan Schürer, Ph.D., CCS Drug Discovery program director, and associate professor of molecular and cellular pharmacology at the UM Miller School of Medicine.
The NIH’s “Illuminating the Druggable Genome“ (IDG) initiative is expected to generate a lot of scientific information from several investigators at leading institutions nationwide. Schürer has been appointed to the IDG’s Resource Dissemination and Outreach Center to organize the incoming data and coordinate project resources. Read more “Genomics meets Big Data in Illuminating the Druggable Genome”